Pentixapharm Holding AG/€PTP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pentixapharm Holding AG
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company specializing in the development of targeted radiopharmaceuticals for diagnostic and therapeutic applications. Its core products include PentixaFor, a Gallium-68-based tracer for diagnosing hematological and solid tumors, and PentixaTher, a Yttrium-90-based therapeutic agent for treating non-Hodgkin lymphomas. Founded in 2019 and headquartered in Berlin, Germany, the company operates additional offices in Würzburg. In July 2024, Pentixapharm acquired Glycotope's target discovery business, enhancing its pipeline with preclinical antibodies against multiple oncology targets. The company's strategic focus on CXCR4 ligand-based radiopharmaceuticals positions it to address a range of cancers and other diseases. (,)
- Ticker
- €PTP
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 38
- Headquarters
- Berlin, Germany
- Website
- www.pentixapharm.com
PTP Metrics
BasicAdvanced
€44M
-
-€0.61
1.46
-
Price and volume
Market cap
€44M
Beta
1.46
52-week high
€3.90
52-week low
€1.33
Average daily volume
12K
Financial strength
Current ratio
1.549
Quick ratio
1.262
Interest coverage (TTM)
-204.63%
Profitability
EBITDA (TTM)
-17.581
Gross margin (TTM)
-2,137.19%
Net profit margin (TTM)
-6,211.57%
Operating margin (TTM)
-7,356.61%
Effective tax rate (TTM)
15.63%
Revenue per employee (TTM)
€10,000
Management effectiveness
Return on assets (TTM)
-24.84%
Return on equity (TTM)
-43.27%
Valuation
Price to revenue (TTM)
184.863
Price to book
1.56
Price to tangible book (TTM)
-22.38
Price to free cash flow (TTM)
-3.06
Free cash flow yield (TTM)
-32.68%
Free cash flow per share (TTM)
-0.59
Growth
Revenue change (TTM)
-86.48%
Earnings per share change (TTM)
-29.44%
PTP Financial Performance
Revenues and expenses
PTP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.